Biomarck Pharmaceuticals Ltd.
USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Biomarck ranks #34,494 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.
- #34,494
- of 49,997 US assignees by volume
- 33rd percentile
- by Innovation Score (30.2/100)
- 15.4
- avg claims per patent
- -60%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R34494 · US Corporation #34,494 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 7 grants
- MID-PACK #34,494/49,997
- PHOTO-FINISH Biodel
- CPC-NARROW A61P · 4 areas
- INNOV-THIN 30.2/100
- CLAIMS-RICH 15.4 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -60% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Biodel AG Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Biomarck’s 30.2 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Biomarck
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Human AI Labs · near 30
Human AI Labs · near
30 score
- Tipping Point Group · near 30
Tipping Point Group · near
30 score
- Advantek International · near 30
Advantek International · near
30 score
- Biomarck Pharmaceuti… · this assignee 30
Biomarck Pharmaceuti… · this assignee
30 score
- Kumho Tire · near 30
Kumho Tire · near
30 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Biomarck's Innovation Score is 30.2/100 (33rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Biomarck?
Each dot is one of Biomarck’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Biomarck’s own 15.4 claims/patent is ABOVE the 15.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Biomarck's grants concentrate
Biomarck Pharmaceuticals Ltd. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2015. By volume, Biomarck sits between Biodel AG Inc. and Bitswave Inc..
Biomarck's three-year grant acceleration
Biomarck Pharmaceuticals Ltd. shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Biomarck's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Biodel
Biodel AG Inc.
7 patents
- Biodyne
Biodyne Co., Ltd.
7 patents
- Bioinvent Interna…
Bioinvent International AB
7 patents
- Biolyph
Biolyph, LLC
7 patents
- Biorestorative Th…
Biorestorative Therapies, Inc.
7 patents
- Biorest
BIOrest Ltd.
7 patents
- Bitdrift
Bitdrift, Inc.
7 patents
- Bitswave
Bitswave Inc.
7 patents
- Biomarck Pharmace… ◀
Biomarck Pharmaceuticals Ltd.
7 patents
What this shows Biomarck holds 7 patents at rank #34,444, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Biomarck
By rank, the assignees closest to #34,444 in granted patent volume.
- Biodel AG Inc. #34,440 · 7 patents
- Biodyne Co., Ltd. #34,441 · 7 patents
- Bioinvent International AB #34,442 · 7 patents
- Biolyph, LLC #34,443 · 7 patents
- Biorestorative Therapies, Inc. #34,445 · 7 patents
- BIOrest Ltd. #34,446 · 7 patents
- Bitdrift, Inc. #34,447 · 7 patents
- Bitswave Inc. #34,448 · 7 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Biomarck's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Biomarck, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Biomarck ranks #2,588 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (30 here).
Biomarck's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
30 33rd percentile higher than 33% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 14.3% |
| 2016 | 1 | 14.3% |
| 2017 | 2 | 28.6% |
| 2018 | 1 | 14.3% |
| 2020 | 1 | 14.3% |
| 2022 | 1 | 14.3% |
Which technologies does Biomarck Pharmaceuticals Ltd. patent most?
Top 4 of 4 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Biomarck Pharmaceuticals Ltd.'s patent record in context - here's where to go next.
- Biomarck Pharmaceuticals Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #34,494 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Biomarck Pharmaceuticals Ltd. against Biodel AG Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 30.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.